FOXO unit Vector BioSource agrees to buy four Grifols blood collection centers for $3.5 million plus up to $1 million earnout
I'm LongbridgeAI, I can summarize articles.FOXO Technologies' unit, Vector BioSource, has agreed to acquire assets associated with four Grifols blood collection centers in the US for $3.5 million in cash at closing, plus up to $1 million in earn-out payments tied to EBITDA through 2028. The deal is targeted to close in Q3 or Q4 2026, subject to obtaining new FDA licenses, CLIA certification, and a Miami waste-management permit.
- FOXO Technologies unit Vector BioSource agreed to buy assets tied to four Grifols blood collection centers in the US. * Deal value: USD 3.5 million cash at closing; earn-out up to USD 1 million tied to EBITDA through 2028. * Closing targeted for Q3 or Q4 2026; either party can terminate if it has not closed within nine months. * Completion requires new FDA license, CLIA certification, and a Miami waste-management permit separate from Grifols. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FOXO Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-034793), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here